Additional Table 1.
Risk of bias assessment of the animal intervention studies based on SYRCLE’s risk of bias tool
| Studies | #1 | #2 | #3 | #4 | #5 | #6 | #7 | #8 | #9 |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Tau pathology | |||||||||
| Du et al. (2013) [1] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 2 | Inline 2 | Inline 2 |
|
| |||||||||
| Lee et al. (2021) [2] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 1 | Inline 2 | Inline 2 |
|
| |||||||||
| Liu et al. (2020) [3] | Inline 1 | Inline 1 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 1 | Inline 2 | Inline 2 |
|
| |||||||||
| Perucho et al. (2012) [4] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 1 | Inline 2 | Inline 2 |
|
| |||||||||
| Portbury et al. (2017) [5] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 1 | Inline 2 | Inline 2 |
|
| |||||||||
| Pupyshev et al. (2022) [6] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 1 | Inline 1 | Inline 2 |
|
| |||||||||
| Holler et al. (2016) [7] | Inline 1 | Inline 1 | Inline 1 | Inline 1 | Inline 2 | Inline 3 | Inline 1 | Inline 2 | Inline 2 |
|
| |||||||||
| Rodríguez-Navarro et al. (2010) [8] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 2 | Inline 2 | Inline 2 |
|
| |||||||||
| Schaeffer et al. (2012) [9] Schaeffer and Goedert (2012) [10] | Inline 1 | Inline 1 | Inline 1 | Inline 1 | Inline 1 | Inline 2 | Inline 1 | Inline 2 | Inline 2 |
|
| |||||||||
| Synucleinopathy | |||||||||
|
| |||||||||
| Darabi et al. (2019) [11] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 1 | Inline 2 | Inline 2 |
|
| |||||||||
| Ferguson et al. (2015) [12] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 2 | Inline 1 | Inline 2 | Inline 2 |
|
| |||||||||
| He et al. (2016) [13] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 2 | Inline 2 | Inline 2 |
|
| |||||||||
| Howson et al. (2019) [14] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 2 | Inline 2 | Inline 2 |
|
| |||||||||
| Kakoty et al. (2021) [15] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 1 | Inline 2 | Inline 2 |
|
| |||||||||
| Lin et al. (2020) [16] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 1 | Inline 2 | Inline 2 |
|
| |||||||||
| Pupyshev et al. (2019) [17] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 1 | Inline 1 | Inline 2 |
|
| |||||||||
| Pupyshev et al. (2021) [18] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 1 | Inline 1 | Inline 2 |
|
| |||||||||
| Sarkar et al. (2014) [19] | Inline 1 | Inline 1 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 1 | Inline 2 | Inline 2 |
|
| |||||||||
| Tanji et al. (2015) [20] | Inline 1 | Inline 1 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 1 | Inline 1 | Inline 2 |
|
| |||||||||
| Polyglutamine tract diseases | |||||||||
|
| |||||||||
| Debnath et al. (2017) [21] Debnath et al. (2019) [22] | Inline 1 | Inline 1 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 1 | Inline 1 | Inline 2 |
|
| |||||||||
| Im et al. (2013) [23] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 1 | Inline 1 | Inline 2 |
|
| |||||||||
| Tanaka et al. (2004) [24] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 1 | Inline 1 | Inline 2 |
|
| |||||||||
| Yang and Yu (2009) [25] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 1 | Inline 1 | Inline 2 |
|
| |||||||||
| Santana et al. (2020) [26] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 2 | Inline 2 | Inline 2 | Inline 2 |
|
| |||||||||
| Chen et al. (2015) [27] | Inline 1 | Inline 1 | Inline 1 | Inline 1 | Inline 1 | Inline 3 | Inline 1 | Inline 2 | Inline 2 |
|
| |||||||||
| Amyotrophic lateral sclerosis | |||||||||
|
| |||||||||
| Castillo et al. (2013) [28] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 2 | Inline 1 | Inline 2 | Inline 2 |
|
| |||||||||
| Li et al. (2015) [29] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 2 | Inline 2 | Inline 2 | Inline 2 |
|
| |||||||||
| Zhang et al. (2014) [30] | Inline 1 | Inline 2 | Inline 1 | Inline 1 | Inline 1 | Inline 2 | Inline 2 | Inline 2 | Inline 2 |
*Green circle: low risk; yellow circle: unclear; red circle: high risk.
Criterion 1: Random sequence generation.
Criterion 2: Baseline characteristics.
Criterion 3: Allocation concealment.
Criterion 4: Random housing.
Criterion 5: Blinding of caregivers and researchers.
Criterion 6: Random outcome assessments.
Criterion 7: Blinding of assessors.
Criterion 8: Incomplete outcome data.
Criterion 9: Selective outcome reporting.